Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 EUR | -0.69% | +1.42% | +4.38% |
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company does not generate enough profits, which is an alarming weak point.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.38% | 147M | - | C | |
-16.43% | 17.21B | B+ | ||
+5.41% | 12.54B | B | ||
+4.64% | 11.71B | B+ | ||
+3.44% | 10.43B | B+ | ||
+28.72% | 8.51B | B | ||
-1.92% | 7.74B | A- | ||
+21.65% | 7.18B | D | ||
+5.12% | 6.55B | B- | ||
+46.09% | 4.5B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings MEDICLIN AG